I’ve elected to start aggregating more content, beyond simply my posts, on Life Science Deal Flow. The starting place is interesting white papers I come across – note the new tab at the top of the LSDF site. If you have a paper you would like reviewed and shared with the LSDF community please be certain to forward it to me at arubenstein@rnaventures.com.

We start our collection with a paper from our friends at NYC-based Thomson Reuters, a leading resource for intelligent information for businesses and professionals, download Biomarkers: An Indispensible Addition to the Drug Development Toolkit [HERE].

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents. The potential of biomarkers to improve decision making, accelerate drug development and reduce development costs is discussed with insight from experts in industry and academia.

An interesting resource to take a look at is the Thomson Reuters BIOMARKERcenter; I’m not certain what the subscription rate for access to this dBase is, nor can I think of another resource similar to this competitive intelligence offering.

Next up comes a paper from our friends at Denver, CO-based Ubiquity, a strategy and creative services company specializing in medical technology product launches, download Social Media Regulations: Not Your Father’s Media [HERE].

The current U.S. regulatory environment as it applies to social media advertising and marketing is a fluid and dynamic environment. In order to understand the current setting for social media as applied to the bioscience industry, it is useful to understand the existing regulations as they pertain to advertising and promotion. Medical devices and biologics are discussed separately, each section providing relevant regulatory background information, followed by a summary of current issues and implications for social media.